Evaluation of the efficacy and safety of oral pentoxifylline in treatment and recovery of patients with COVID-19 admitted in Rasoul Akram and firoozgar hospitals treated with routine protocols, A randomized controlled clinical trial

Iran University of Medical Sciences0 个研究点目标入组 150 人开始时间: 待定最近更新: 2022年3月8日

试验速览

暂无简介。

•Admitted patients with COVID-19
•Moderate to severe disease
•Stable patients
•Patients should not have bleeding disorders
•Patients do not have a history of heart attack and stroke
•Patients without history of ocular or cerebral hemorrhage
•No pregnancy or breastfeeding
•Patients without history of intolerance to PTX or other xanthines such as caffeine, theophylline and tobromine
•Patients without gastric ulcers
•Patient without history of porphyria
•Patients with no prominent renal or hepatic or cardiac dysfunction
•Patients without history of major surgery in the past 2 weeks
•Patients without history of cancer
•Patients without need to use any therapeutic blood thinners, including aspirin and warfarin

•Allergy to any of the drugs studied, including pentoxifylline
•Occurrence of any bleeding during the study (in the stomach, brain, eyes, ...)
•Drug intolerance or the occurrence of any severe side effects during treatment, such as gastrointestinal intolerance, does not respond to pre-determined measures of anti-acids... or the occurrence of skin drug reactions to the received treatment protocol and ...
•Being pregnant during the study
•Occurrence of heart attack and stroke during the study
•Drop in pressure below 10 mm Hg or instability of the patient's vital signs
•Require intubation during study or hospitalization in the ICU
•Increase in the severity of COVID-19 disease during the study so that the need for hospitalization in the ICU or the need to change the treatment protocol
•The use of a therapeutic drug other than the standard drug in this study

发起方